## Han-Chieh Lin

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8633568/publications.pdf

Version: 2024-02-01

164 papers 4,028 citations

147566 31 h-index 54 g-index

165 all docs 165
docs citations

165 times ranked 5237 citing authors

#	Article	IF	CITATIONS
1	Myosteatosis, but not Sarcopenia, Predisposes NAFLD Subjects to Early Steatohepatitis and Fibrosis Progression. Clinical Gastroenterology and Hepatology, 2023, 21, 388-397.e10.	2.4	29
2	Impact of Sofosbuvir-Based Direct-Acting Antivirals on Renal Function in Chronic Hepatitis C Patients With Impaired Renal Function: A Large Cohort Study From the Nationwide HCV Registry Program (TACR). Clinical Gastroenterology and Hepatology, 2022, 20, 1151-1162.e6.	2.4	14
3	APASL clinical practice guidance: the diagnosis and management of patients with primary biliary cholangitis. Hepatology International, 2022, 16, 1-23.	1.9	45
4	Ledipasvir/sofosbuvir for HCV genotype $1, 2, 4\hat{a} \in 6$ infection: Real-world evidence from a nationwide registry in Taiwan. Journal of the Formosan Medical Association, 2022, 121, 1567-1578.	0.8	2
5	Factors Associated with Significant Platelet Count Improvement in Thrombocytopenic Chronic Hepatitis C Patients Receiving Direct-Acting Antivirals. Viruses, 2022, 14, 333.	1.5	2
6	Sofosbuvir/Velpatasvir for HepatitisÂC Virus Infection: Real-World Effectiveness and Safety from a Nationwide Registry in Taiwan. Infectious Diseases and Therapy, 2022, 11, 485-500.	1.8	13
7	Muscle alterations are independently associated with significant fibrosis in patients with nonalcoholic fatty liver disease. Liver International, 2021, 41, 494-504.	1.9	28
8	Active Vitamin D <sub>3</sub> Treatment Attenuated Bacterial Translocation via Improving Intestinal Barriers in Cirrhotic Rats. Molecular Nutrition and Food Research, 2021, 65, e2000937.	1.5	20
9	Intestinal SIRT1 Deficiency-Related Intestinal Inflammation and Dysbiosis Aggravate TNFα-Mediated Renal Dysfunction in Cirrhotic Ascitic Mice. International Journal of Molecular Sciences, 2021, 22, 1233.	1.8	6
10	Factors associated with treatment failure of directâ€acting antivirals for chronic hepatitis C: A realâ€world nationwide hepatitis C virus registry programme in Taiwan. Liver International, 2021, 41, 1265-1277.	1.9	29
11	Longâ€ŧerm risk of endâ€stage renal diseases with maintenance dialysis among chronic hepatitis C patients after antiviral therapy in Taiwan. Journal of Gastroenterology and Hepatology (Australia), 2021, 36, 2247-2254.	1.4	3
12	Toward a new landscape for the mechanism of immunosuppression in hepatocellular carcinoma. Hepatology International, 2021, 15, 287-289.	1.9	2
13	Persistent liver inflammation in chronic hepatitis C patients with advanced fibrosis after direct-acting antivirals induced sustained virological response. Journal of the Chinese Medical Association, 2021, 84, 472-477.	0.6	2
14	Non-Selective Beta-Blockers Decrease Infection, Acute Kidney Injury Episodes, and Ameliorate Sarcopenic Changes in Patients with Cirrhosis: A Propensity-Score Matching Tertiary-Center Cohort Study. Journal of Clinical Medicine, 2021, 10, 2244.	1.0	4
15	Hepatitis C virus eradication decreases the risks of liver cirrhosis and cirrhosisâ€related complications (Taiwanese chronic hepatitis C cohort). Journal of Gastroenterology and Hepatology (Australia), 2021, 36, 2884-2892.	1.4	10
16	Eritoran Attenuates Hepatic Inflammation and Fibrosis in Mice with Chronic Liver Injury. Cells, 2021, 10, 1562.	1.8	12
17	Roles and mechanisms of circulating CEACAM1 in the cirrhosis-related intestinal hyperpermeability: in vitro approach. Journal of the Chinese Medical Association, 2021, 84, 851-859.	0.6	1
18	Long-term outcome of liver complications in patients with chronic HBV/HCV co-infection after antiviral therapy: a real-world nationwide study on Taiwanese Chronic Hepatitis C Cohort (T-COACH). Hepatology International, 2021, 15, 1109-1121.	1.9	4

#	Article	IF	CITATIONS
19	Deletion of intestinal SIRT1 exacerbated muscle wasting in cirrhotic mice by decreasing the intestinal concentration of short-chain fatty acids and inflammation. Journal of Pharmacological Sciences, 2021, 147, 376-385.	1.1	8
20	Mac-2 binding protein glycosylation isomer is a potential biomarker to predict portal hypertension and bacterial infection in cirrhotic patients. PLoS ONE, 2021, 16, e0258589.	1.1	5
21	Pioglitazone Ameliorates Acute Endotoxemia-Induced Acute on Chronic Renal Dysfunction in Cirrhotic Ascitic Rats. Cells, 2021, 10, 3044.	1.8	5
22	Predictors of long-term recurrence and survival after resection of HBV-related hepatocellular carcinoma: the role of HBsAg. American Journal of Cancer Research, 2021, 11, 3711-3725.	1.4	4
23	Comparable benefits of HCV eradication by direct acting antivirals and interferon-based therapy in patients with hepatocellular carcinoma undergoing surgical resection. American Journal of Cancer Research, 2021, 11, 5526-5542.	1.4	0
24	Nationwide registry of glecaprevir plus pibrentasvir in the treatment of HCV in Taiwan. Scientific Reports, 2021, 11, 23473.	1.6	8
25	Aspirin is associated with low recurrent risk in hepatitis B virus-related hepatocellular carcinoma patients after curative resection. Journal of the Formosan Medical Association, 2020, 119, 218-229.	0.8	19
26	Association between esophagogastric varices in hepatocellular carcinoma and poor prognosis after transarterial chemoembolization: A propensity score matching analysis. Journal of the Formosan Medical Association, 2020, 119, 610-620.	0.8	13
27	Lactobacillus plantarum PS128 Ameliorated Visceral Hypersensitivity in Rats Through the Gut–Brain Axis. Probiotics and Antimicrobial Proteins, 2020, 12, 980-993.	1.9	13
28	Low dose of propranolol treatment is associated with better survival in cirrhotic patients with hepatic encephalopathy. European Journal of Gastroenterology and Hepatology, 2020, 32, 365-372.	0.8	2
29	Extrahepatic Malignancy Among Patients With Chronic Hepatitis C After Antiviral Therapy: A Real-World Nationwide Study on Taiwanese Chronic Hepatitis C Cohort (T-COACH). American Journal of Gastroenterology, 2020, 115, 1226-1235.	0.2	19
30	A comparison of prognoses between surgical resection and radiofrequency ablation therapy for patients with hepatocellular carcinoma and esophagogastric varices. Scientific Reports, 2020, 10, 17259.	1.6	7
31	Unhealthy lifestyle habits and physical inactivity among Asian patients with nonâ€alcoholic fatty liver disease. Liver International, 2020, 40, 2719-2731.	1.9	32
32	Successful Antiviral Therapy Reduces Risk of Schizophrenia Among Chronic Hepatitis C Patients: A Nationwide Real-World Taiwanese Cohort (T-COACH). Open Forum Infectious Diseases, 2020, 7, ofaa397.	0.4	3
33	Virological and immunological predictors of long term outcomes of peginterferon alfa-2a therapy for HBeAg-negative chronic hepatitis B. Journal of the Formosan Medical Association, 2020, 120, 1676-1685.	0.8	3
34	2020 Taiwan consensus statement on the management of hepatitis C: part (I) general population. Journal of the Formosan Medical Association, 2020, 119, 1019-1040.	0.8	60
35	SIRT1-dependent mechanisms and effects of resveratrol for amelioration of muscle wasting in NASH mice. BMJ Open Gastroenterology, 2020, 7, e000381.	1.1	5
36	Modelling NAFLD disease burden in four Asian regions—2019â€2030. Alimentary Pharmacology and Therapeutics, 2020, 51, 801-811.	1.9	92

#	Article	IF	CITATIONS
37	Propranolol Suppresses the T-Helper Cell Depletion-Related Immune Dysfunction in Cirrhotic Mice. Cells, 2020, 9, 604.	1.8	12
38	Editorial: increasing burden of nonalcoholic fatty liver diseaseâ€"a call to action. Authors' reply. Alimentary Pharmacology and Therapeutics, 2020, 51, 1430-1432.	1.9	0
39	Antibiotic use in patients with acute cholecystitis after percutaneous cholecystostomy. Journal of the Chinese Medical Association, 2020, 83, 134-140.	0.6	5
40	Liver stiffness measured by acoustic radiation force impulse elastography predicted prognoses of hepatocellular carcinoma after radiofrequency ablation. Scientific Reports, 2020, 10, 2006.	1.6	7
41	2020 Taiwan consensus statement on the management of hepatitis C: Part (II) special populations. Journal of the Formosan Medical Association, 2020, 119, 1135-1157.	0.8	69
42	Sustained virological response to hepatitis C therapy does not decrease the incidence of systemic lupus erythematosus or rheumatoid arthritis. Scientific Reports, 2020, 10, 5372.	1.6	4
43	Propranolol Is Associated with Lower Risk of Incidence of Hepatocellular Carcinoma in Patients with Alcoholic Cirrhosis: A Tertiary-Center Study and Indirect Comparison with Meta-Analysis. Gastroenterology Research and Practice, 2020, 2020, 1-7.	0.7	5
44	Obeticholic acid ameliorates hepatorenal syndrome in ascitic cirrhotic rats by down-regulating the renal 8-iso-PGF2α-activated COX-TXA2 pathway. Clinical Science, 2020, 134, 2055-2073.	1.8	9
45	Early echocardiographic signs of diastolic dysfunction predict acute kidney injury in cirrhotic patients. Journal of the Chinese Medical Association, 2020, 83, 984-990.	0.6	6
46	A new ALBIâ€based model to predict survival after transarterial chemoembolization for BCLC stage B hepatocellular carcinoma. Liver International, 2019, 39, 1704-1712.	1.9	58
47	Elafibranor Inhibits Chronic Kidney Disease Progression in NASH Mice. BioMed Research International, 2019, 2019, 1-14.	0.9	13
48	Keep scalpel sheathed: A metastatic invasive ductal carcinoma mimics primary linitis plastica. Advances in Digestive Medicine, 2019, 6, 36-39.	0.1	0
49	Altered cognitive control network is related to psychometric and biochemical profiles in covert hepatic encephalopathy. Scientific Reports, 2019, 9, 6580.	1.6	8
50	Intestinal iNKT cells migrate to liver and contribute to hepatocyte apoptosis during alcoholic liver disease. American Journal of Physiology - Renal Physiology, 2019, 316, G585-G597.	1.6	23
51	Human relaxin-2 attenuates hepatic steatosis and fibrosis in mice with non-alcoholic fatty liver disease. Laboratory Investigation, 2019, 99, 1203-1216.	1.7	22
52	Albumin-bilirubin grade may determine the outcomes of patients with very early stage hepatocellular carcinoma after radiofrequency ablation therapy. Journal of the Chinese Medical Association, 2019, 82, 2-10.	0.6	16
53	Proton Pump Inhibitors and Risk of Hepatocellular Carcinoma in Patients With Chronic Hepatitis B or C. Hepatology, 2019, 69, 1151-1164.	3.6	22
54	Elafibranor interrupts adipose dysfunction-mediated gut and liver injury in mice with alcoholic steatohepatitis. Clinical Science, 2019, 133, 531-544.	1.8	12

#	Article	IF	CITATIONS
55	Dabigatran Reduces Liver Fibrosis in Thioacetamide-Injured Rats. Digestive Diseases and Sciences, 2019, 64, 102-112.	1.1	26
56	Combination of albumin-bilirubin grade and platelets to predict a compensated patient with hepatocellular carcinomaÂwho does not require endoscopic screening for esophageal varices. Gastrointestinal Endoscopy, 2018, 88, 230-239.e2.	0.5	30
57	Impact of etiological treatment on prognosis. Hepatology International, 2018, 12, 56-67.	1.9	12
58	Validation of the albuminâ€bilirubin gradeâ€based integrated model as a predictor for sorafenibâ€failed hepatocellular carcinoma. Liver International, 2018, 38, 321-330.	1.9	37
59	Effects and mechanisms of caffeine to improve immunological and metabolic abnormalities in diet-induced obese rats. American Journal of Physiology - Endocrinology and Metabolism, 2018, 314, E433-E447.	1.8	20
60	Correlation and prognostic accuracy between noninvasive liver fibrosismarkers and portal pressure in cirrhosis: Role of ALBI score. PLoS ONE, 2018, 13, e0208903.	1.1	30
61	Use of prokinetic agents or antibiotics is associated with the occurrence of spontaneous bacterial peritonitis in cirrhotic patients. Journal of the Chinese Medical Association, 2018, 81, 935-941.	0.6	2
62	The Prognosis of Single Large Hepatocellular Carcinoma Was Distinct from Barcelona Clinic Liver Cancer Stage A or B: The Role of Albumin-Bilirubin Grade. Liver Cancer, 2018, 7, 335-358.	4.2	27
63	Risk of renal events during tenofovir disoproxil fumarate and entecavir antiviral prophylaxis in HBsAgâ€positive cancer patients undergoing chemotherapy. Journal of Viral Hepatitis, 2018, 25, 1599-1607.	1.0	9
64	Serum pentraxin-3 and tumor necrosis factor-like weak inducer of apoptosis (TWEAK) predict severity of infections in acute decompensated cirrhotic patients. Journal of Microbiology, Immunology and Infection, 2017, 50, 905-914.	1.5	11
65	The telomere-binding protein TRF2 is required for metronomic therapeutic effects of gemcitabine and capecitabine. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2017, 1863, 917-928.	1.8	1
66	Scientific publications in gastroenterology and hepatology in Taiwan: An analysis of Web of Science from 1993 to 2013. Journal of the Chinese Medical Association, 2017, 80, 80-85.	0.6	9
67	Mechanisms of the prevention and inhibition of the progression and development of nonâ€alcoholic steatohepatitis by genetic and pharmacological decoy receptor 3 supplementation. Hepatology Research, 2017, 47, 1260-1271.	1.8	8
68	The impact of esophagogastric varices on the prognosis of patients with hepatocellular carcinoma. Scientific Reports, 2017, 7, 42577.	1.6	25
69	Acute kidney injury predicts mortality in cirrhotic patients with gastric variceal bleeding. Journal of Gastroenterology and Hepatology (Australia), 2017, 32, 1859-1866.	1.4	18
70	Decoy receptor 3 analogous supplement protects steatotic rat liver from ischemia–reperfusion injury. Journal of the Chinese Medical Association, 2017, 80, 391-400.	0.6	7
71	Hepatocellular Carcinoma: Nomograms Based on the Albumin-Bilirubin Grade to Assess the Outcomes of Radiofrequency Ablation. Radiology, 2017, 285, 670-680.	3.6	88
72	Metallic Stent Expansion Rate at Day One Predicts Stent Patency in Patients with Gastric Outlet Obstruction. Digestive Diseases and Sciences, 2017, 62, 1286-1294.	1.1	16

#	Article	IF	CITATIONS
73	Homocysteine deteriorates intrahepatic derangement and portal-systemic collaterals in cirrhotic rats. Clinical Science, 2017, 131, 69-86.	1.8	6
74	The effects of pioglitazone in cirrhotic rats with hepatopulmonary syndrome. Journal of the Chinese Medical Association, 2017, 80, 683-689.	0.6	8
75	The beneficial effects of curcumin in cirrhotic rats with portal hypertension. Bioscience Reports, 2017, 37, .	1.1	14
76	Higher platelet counts are associated with metabolic syndrome independent of fatty liver diagnosis. Journal of the Chinese Medical Association, 2017, 80, 125-132.	0.6	24
77	The impact of clinically significant portal hypertension on the prognosis of patients with hepatocellular carcinoma after radiofrequency ablation: a propensity score matching analysis. European Radiology, 2017, 27, 2600-2609.	2.3	13
78	ALBI and PALBI grade predict survival for HCC across treatment modalities and BCLC stages in the MELD Era. Journal of Gastroenterology and Hepatology (Australia), 2017, 32, 879-886.	1.4	126
79	Proton Pump Inhibitors Increase Risk for Hepatic Encephalopathy in Patients With Cirrhosis in A Population Study. Gastroenterology, 2017, 152, 134-141.	0.6	133
80	Risk of recurrence in chronic hepatitis B patients developing hepatocellular carcinoma with antiviral secondary prevention failure. PLoS ONE, 2017, 12, e0188552.	1,1	6
81	Fatty Liver Index and Lipid Accumulation Product Can Predict Metabolic Syndrome in Subjects without Fatty Liver Disease. Gastroenterology Research and Practice, 2017, 2017, 1-12.	0.7	14
82	Comparison between tenofovir disoproxil fumarate and entecavir treatment in realâ€world clinical practice. Advances in Digestive Medicine, 2017, 4, 87-93.	0.1	0
83	Uterine cervical squamous cell carcinoma with duodenal metastasis causes obstructive jaundice. Advances in Digestive Medicine, 2017, 4, 76-79.	0.1	0
84	TLR4/CD14 Variants-Related Serologic and Immunologic Dys-Regulations Predict Severe Sepsis in Febrile De-Compensated Cirrhotic Patients. PLoS ONE, 2016, 11, e0166458.	1.1	4
85	2'â€Hydroxyflavanone ameliorates mesenteric angiogenesis and portalâ€systemic collaterals in rats with liver fibrosis. Journal of Gastroenterology and Hepatology (Australia), 2016, 31, 1045-1051.	1.4	6
86	Low air temperature increases the risk of oesophageal variceal bleeding: a population and hospitalâ€based caseâ€crossover study in Taiwan. Liver International, 2016, 36, 856-864.	1.9	4
87	Endothelin receptor blockers reduce shunting and angiogenesis in cirrhotic rats. European Journal of Clinical Investigation, 2016, 46, 572-580.	1.7	21
88	Down-regulation of common NFκB-iNOS pathway by chronic Thalidomide treatment improves Hepatopulmonary Syndrome and Muscle Wasting in rats with Biliary Cirrhosis. Scientific Reports, 2016, 6, 39405.	1.6	25
89	Aliskiren Reduces Hepatic steatosis and Epididymal Fat Mass and Increases Skeletal Muscle Insulin Sensitivity in High-Fat Diet-Fed Mice. Scientific Reports, 2016, 6, 18899.	1.6	18
90	Oncogenic circuit constituted by Ser31-HBx and Akt increases risks of chronic hepatitis and hepatocellular carcinoma. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2016, 1862, 837-849.	1.8	3

#	Article	IF	Citations
91	Helicobacter pylori-induced chronic inflammation causes telomere shortening of gastric mucosa by promoting PARP-1-mediated non-homologous end joining of DNA. Archives of Biochemistry and Biophysics, 2016, 606, 90-98.	1.4	25
92	Antiplatelet Therapy is Associated with a Better Prognosis for Patients with Hepatitis B Virus-Related Hepatocellular Carcinoma after Liver Resection. Annals of Surgical Oncology, 2016, 23, 874-883.	0.7	51
93	Predictors of response to pegylated interferon in chronic hepatitis B: a real-world hospital-based analysis. Scientific Reports, 2016, 6, 29605.	1.6	37
94	Proposal and validation of a new model to estimate survival for hepatocellular carcinoma patients. European Journal of Cancer, 2016, 63, 25-33.	1.3	40
95	Analysis of baseline hepatitis B virus DNA levels in chronic hepatitis B patients with non-hematological malignancies prior to the initiation of cancer chemotherapy. Molecular and Clinical Oncology, 2016, 5, 165-170.	0.4	1
96	Peripheral injection of pancreatic polypeptide enhances colonic transit without eliciting anxiety or altering colonic secretion in rats. Neuropeptides, 2016, 55, 67-71.	0.9	5
97	Nomogram of the Barcelona Clinic Liver Cancer system for individual prognostic prediction in hepatocellular carcinoma. Liver International, 2016, 36, 1498-1506.	1.9	25
98	Akt phosphorylates myc-associated zinc finger protein (MAZ), releases P-MAZ from the p53 promoter, and activates p53 transcription. Cancer Letters, 2016, 375, 9-19.	3.2	15
99	Establishing a risk scoring system for predicting erosive esophagitis. Advances in Digestive Medicine, 2016, 3, 95-100.	0.1	2
100	Prognosis of hepatocellular carcinoma: Assessment of eleven staging systems. Journal of Hepatology, 2016, 64, 601-608.	1.8	220
101	N -Acetyltransferase 2 ( NAT2 ) genetic variation and the susceptibility to noncardiac gastric adenocarcinoma in Taiwan. Journal of the Chinese Medical Association, 2016, 79, 105-110.	0.6	4
102	Surgical Resection is Better than Transarterial Chemoembolization for Patients with Hepatocellular Carcinoma Beyond the Milan Criteria: A Prognostic Nomogram Study. Annals of Surgical Oncology, 2016, 23, 994-1002.	0.7	38
103	Clopidogrel inhibits angiogenesis of gastric ulcer healing via downregulation of vascular endothelial growth factor receptor 2. Journal of the Formosan Medical Association, 2016, 115, 764-772.	0.8	30
104	Solitary Large Hepatocellular Carcinoma: Staging and Treatment Strategy. PLoS ONE, 2016, 11, e0155588.	1.1	37
105	Rosuvastatin improves hepatopulmonary syndrome through inhibition of inflammatory angiogenesis of lung. Clinical Science, 2015, 129, 449-460.	1.8	34
106	Alteration of intrahepatic microcirculation in cirrhotic livers. Journal of the Chinese Medical Association, 2015, 78, 430-437.	0.6	8
107	External Validation of Fatty Liver Index for Identifying Ultrasonographic Fatty Liver in a Large-Scale Cross-Sectional Study in Taiwan. PLoS ONE, 2015, 10, e0120443.	1.1	105
108	The Beneficial Effects of P2X7 Antagonism in Rats with Bile Duct Ligation-induced Cirrhosis. PLoS ONE, 2015, 10, e0124654.	1.1	26

#	Article	IF	Citations
109	Detecting Minimal Hepatic Encephalopathy in an Endemic Country for Hepatitis B: The Role of Psychometrics and Serum IL-6. PLoS ONE, 2015, 10, e0128437.	1.1	20
110	Anti-hepatitis C virus seropositivity is not associated with metabolic syndrome irrespective of age, gender and fibrosis. Annals of Hepatology, 2015, 14, 181-189.	0.6	18
111	Determinants of Survival After Sorafenib Failure in Patients With BCLC-C Hepatocellular Carcinoma in Real-World Practice. Medicine (United States), 2015, 94, e688.	0.4	30
112	Vomiting and diarrhea in a woman with systemic lupus erythematosus. Journal of the Chinese Medical Association, 2015, 78, 133-135.	0.6	3
113	Risk of Cancer in Patients with Cholecystitis: A Nationwide Population-based Study. American Journal of Medicine, 2015, 128, 185-191.	0.6	9
114	P2X7 Receptor Mediates Spinal Microglia Activation of Visceral Hyperalgesia in a Rat Model of Chronic Pancreatitis. Cellular and Molecular Gastroenterology and Hepatology, 2015, 1, 710-720.e5.	2.3	10
115	Allo-transplantation of mesenchymal stem cells attenuates hepatic injury through IL1Ra dependent macrophage switch in a mouse model of liver disease. Journal of Hepatology, 2015, 63, 1405-1412.	1.8	65
116	The Impact of Spironolactone on the Severity of Portal-Systemic Collaterals and Hepatic Encephalopathy in Cirrhotic Rats. Journal of Pharmacology and Experimental Therapeutics, 2015, 355, 117-124.	1.3	9
117	Using Serum $\hat{l}_{\pm}$ -Fetoprotein for Prognostic Prediction in Patients with Hepatocellular Carcinoma: What is the Most Optimal Cutoff?. PLoS ONE, 2015, 10, e0118825.	1.1	36
118	Anti-hepatitis C virus seropositivity is not associated with metabolic syndrome irrespective of age, gender and fibrosis. Annals of Hepatology, 2015, 14, 181-9.	0.6	12
119	Adrenal Dysfunction in Portal Hypertensive Rats with Acute Hemorrhage. PLoS ONE, 2014, 9, e92093.	1.1	3
120	A New Child-Turcotte-Pugh Class 0 for Patients with Hepatocellular Carcinoma: Determinants, Prognostic Impact and Ability to Improve the Current Staging Systems. PLoS ONE, 2014, 9, e99115.	1.1	8
121	Beneficial effects of dual vascular endothelial growth factor receptor/fibroblast growth factor receptor inhibitor brivanib alaninate in cirrhotic portal hypertensive rats. Journal of Gastroenterology and Hepatology (Australia), 2014, 29, 1073-1082.	1.4	26
122	Stromal tumor presents as a large extragastrointestinal mass in the abdominal cavity. Advances in Digestive Medicine, 2014, 1, 136-139.	0.1	0
123	Hypertension is an important predictor of recurrent colorectal adenoma after screening colonoscopy with adenoma polypectomy. Journal of the Chinese Medical Association, 2014, 77, 508-512.	0.6	22
124	Long-term cannabinoid type 2 receptor agonist therapy decreases bacterial translocation in rats with cirrhosis and ascites. Journal of Hepatology, 2014, 61, 1004-1013.	1.8	41
125	Outcome for selfâ€expandable metal stents inÂpatientsÂwith malignant gastroduodenal obstruction: A single center experience. Advances in Digestive Medicine, 2014, 1, 1-8.	0.1	4
126	Toward an Improved Definition of Acute-on-Chronic Liver Failure. Gastroenterology, 2014, 147, 4-10.	0.6	255

#	Article	IF	Citations
127	Decrypting Cryptogenic Hepatocellular Carcinoma: Clinical Manifestations, Prognostic Factors and Long-Term Survival by Propensity Score Model. PLoS ONE, 2014, 9, e89373.	1.1	13
128	Alcoholism worsens the survival of patients with hepatitis B virus and C virus-related hepatocellular carcinoma. Hepatology International, 2013, 7, 645-654.	1.9	17
129	Is transarterial chemoembolization beneficial for patients with diffuse infiltrative hepatocellular carcinoma?. Hepatology International, 2013, 7, 676-682.	1.9	6
130	Ascites in patients with hepatocellular carcinoma: prevalence, associated factors, prognostic impact, and staging strategy. Hepatology International, 2013, 7, 188-198.	1.9	36
131	Inverse Association between Hepatitis B Virus Infection and Fatty Liver Disease: A Large-Scale Study in Populations Seeking for Check-Up. PLoS ONE, 2013, 8, e72049.	1.1	76
132	Response to theâ€ <scp>ADMA</scp> and hepatic endothelial dysfunction in cirrhosisâ€the <scp>DDAH</scp> isoform is the key. Liver International, 2012, 32, 1187-1187.	1.9	0
133	Efficacy of non-selective $\hat{I}^2$ -blockers as adjunct to endoscopic prophylactic treatment for gastric variceal bleeding: A randomized controlled trial. Journal of Hepatology, 2012, 56, 1025-1032.	1.8	150
134	Transarterial chemoembolization can prolong survival for patients with metastatic hepatocellular carcinoma: a propensity score matching analysis. Hepatology International, 2012, 6, 753-762.	1.9	20
135	The relationship between endotoxemia and hepatic endocannabinoids in cirrhotic rats with portal hypertension. Journal of Hepatology, 2011, 54, 1145-1153.	1.8	30
136	Portal Hypotensive Effects of Tetrandrine and Verapamil in Portal Hypertensive Rats. Journal of Pharmacy and Pharmacology, 2011, 49, 85-88.	1.2	12
137	Comparative Analysis of Noninvasive Models to Predict Early Liver Fibrosis in Hepatitis B e Antigen-negative Chronic Hepatitis B. Journal of Clinical Gastroenterology, 2011, 45, 278-285.	1.1	28
138	Early identification of poor responders to transarterial chemoembolization for hepatocellular carcinoma. Hepatology International, 2011, 5, 975-984.	1.9	13
139	Corticosteroids therapy and peptic ulcer disease in nephrotic syndrome patients. British Journal of Clinical Pharmacology, 2010, 70, 756-761.	1.1	6
140	The safety and probable therapeutic effect of routine use of antibiotics and simultaneously treating bleeding gastric varices by using endoscopic cyanoacrylate injection and concomitant esophageal varices with banding ligation: a pilot study. Gastrointestinal Endoscopy, 2010, 71, 1141-1149.	0.5	11
141	A randomized trial of endoscopic cyanoacrylate injection for acute gastric variceal bleeding: 0.5 mL versus 1.0 mL. Gastrointestinal Endoscopy, 2009, 70, 668-675.	0.5	44
142	Hemodynamic effects of one week of carvedilol administration on cirrhotic rats. Journal of Gastroenterology, 2006, 41, 361-368.	2.3	12
143	Vascular contractile response and signal transduction in endothelium-denuded aorta from cirrhotic rats. World Journal of Gastroenterology, 2005, 11, 2306.	1.4	8
144	Acute Administration of Carvedilol is More Effective than Propranolol Plus Isosorbide-5-Mononitrate in the Reduction of Portal Pressure in Patients with Viral Cirrhosis. American Journal of Gastroenterology, 2004, 99, 1953-1958.	0.2	48

#	Article	IF	Citations
145	Effect of anaemia on haemodynamics in patients with cirrhosis. Journal of Gastroenterology and Hepatology (Australia), 2002, 14, 370-375.	1.4	12
146	Portopulmonary hypertension: distinctive hemodynamic and clinical manifestations. Journal of Gastroenterology, 2001, 36, 181-186.	2.3	58
147	Splanchnic hyposensitivity to glypressin in a haemorrhage/transfused rat model of portal hypertension: role of nitric oxide and bradykinin. Clinical Science, 2000, 99, 475-482.	1.8	8
148	Portal hypertensive effects of combined terlipressin and DL-028, a synthetic ?1adrenoceptor antagonist administration on anesthetized portal hypertensive rats. Liver International, 1999, 19, 129-134.	1.9	3
149	Effects of vasopressin on portal-systemic collaterals in portal hypertensive rats: Role of nitric oxide and prostaglandin. Hepatology, 1999, 30, 630-635.	3.6	63
150	Haemodynamic effects of chronic octreotide and tetrandrine administration in portal hypertensive rats. Journal of Gastroenterology and Hepatology (Australia), 1998, 13, 266-272.	1.4	8
151	CASE REPORT: Successful obliteration of a bleeding duodenal varix using endoscopic ligation. Journal of Gastroenterology and Hepatology (Australia), 1998, 13, 591-593.	1.4	18
152	The Clinical Significance of Hyperamylasemia in Organophosphate Poisoning. Journal of Toxicology: Clinical Toxicology, 1998, 36, 673-681.	1.5	34
153	Prolonged bleeding time: A new clinical manifestation of hepatocellular carcinoma?. Journal of Gastroenterology and Hepatology (Australia), 1997, 12, 563-568.	1.4	2
154	Haemodynamic effects of chronic tetrandrine treatment in portal hypertensive rats. Journal of Gastroenterology and Hepatology (Australia), 1997, 12, 585-589.	1.4	11
155	Prevalence of gastric ulcer in cirrhotic patients and its relation to portal hypertension. Journal of Gastroenterology and Hepatology (Australia), 1996, 11, 59-64.	1.4	63
156	Hyperglucagonaemia in cirrhotic patients and its relationship to the severity of cirrhosis and haemodynamic values. Journal of Gastroenterology and Hepatology (Australia), 1996, 11, 422-428.	1.4	12
157	Haemodynamic effects of a combination of propranolol and clonidine in patients with post-hepatitic cirrhosis. Journal of Gastroenterology and Hepatology (Australia), 1995, 10, 281-286.	1.4	7
158	Comparison of endoscopic variceal injection sclerotherapy and ligation for the treatment of esophageal variceal hemorrhage: A prospective randomized trial. Hepatology, 1995, 21, 1517-1522.	3.6	183
159	Transjugular liver biopsy: Comparison with percutaneous liver biopsy. Journal of Gastroenterology and Hepatology (Australia), 1994, 9, 457-461.	1.4	22
160	Prevalence of anti-HCV among Chinese patients with acute and chronic liver disease. Journal of Gastroenterology and Hepatology (Australia), 1992, 7, 113-116.	1.4	8
161	Snake skin pattern gastropathy in cirrhotic patients. Journal of Gastroenterology and Hepatology (Australia), 1991, 6, 145-149.	1.4	32
162	Hyposensitivity to vasopressin in patients with hepatitis B–related cirrhosis during acute variceal hemorrhage. Hepatology, 1991, 13, 407-412.	3.6	28

## Han-Chieh Lin

#	Article	IF	CITATIONS
163	Utility of sono-graphic gallbladder wall patterns in differentiating malignant from cirrhotic ascites. Journal of Clinical Ultrasound, 1989, 17, 187-192.	0.4	10
164	Phase II study of mitoxantrone in unresectable primary hepatocellular carcinoma following hepatitis B infection. Cancer Chemotherapy and Pharmacology, 1989, 23, 54-6.	1.1	26